A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Clinical trial NCT07234162 · RECRUITING

Trial details

NCT number: NCT07234162
Sponsor: Dizal Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Peripheral T-cell Lymphoma

Start date: 2024-05-13
Primary completion: 2027-11-30
Enrollment: 218

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.